Chimerix

Chimerix

NC - Durham
Biotechnology
WebsiteLinkedInCareers Page

Focus: Small Molecules

Chimerix is a life sciences company focused on Small Molecules.

Oncology
Funding Stage
PUBLIC
Open Jobs
0

Products & Portfolio (1)

MODEYSO
dordaviprone
Launch
ORAL · CAPSULE
(ClpP). Dordaviprone also inhibits the dopamine D2 receptor. Diffuse midline gliomas harboring an H3 K27M mutation are associated with the loss of H3 K27 trimethylation. In-vitro, dordaviprone activated the integrated stress response, induced apoptosis, and altered mitochondrial metabolism leading to restored histone H3 K27 trimethylation in H3 K27M-mutant diffuse glioma models. Dordaviprone exhibited antitumor activity in cell-based assays and in vivo models of H3 K27M-mutant diffuse glioma.
older with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy
2025
0

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Portfolio: 1 approved product
Top TAs: Oncology
Portfolio Health
Launch1 (100%)
1 total products
Therapeutic Area Focus
Oncology
1 marketed
Marketed
Pipeline

Hiring Trend

Stable
0
Open Roles
+0
Added
-0
Filled/Removed

Based on last 4 crawl cycles